Mitchell Chan
CIK: 0001789335
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Sep 1, 2026RGNX
REGENXBIO Inc.
Tax Payment(F)Direct4.9K shares at avg. $9.32$46K - May 6, 2026AVTX
Avalo Therapeutics, Inc.
Sale(S)Direct3.2K shares at avg. $22.88$72K - Jan 6, 2026RGNX
REGENXBIO Inc.
Award(A)Direct73.7K shares- - Sep 1, 2025RGNX
REGENXBIO Inc.
Tax Payment(F)Direct4.9K shares at avg. $8.93$44K - Jun 17, 2025AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.1K shares- - Mar 28, 2025AVTX
Avalo Therapeutics, Inc.
Exercise(M)Direct3.2K shares- - Jan 2, 2025RGNX
REGENXBIO Inc.
Award(A)DirectStock Options (Right to buy)
62.5K shares- - Sep 16, 2024RGNX
REGENXBIO Inc.
Award(A)Direct58.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 1, 2026 |  RGNX REGENXBIO Inc. | Tax Payment(F) | 4,902 | $9.32 | $45,687 | Direct |
| May 6, 2026 |  AVTX Avalo Therapeutics, Inc. | Sale(S) | 3,167 | $22.88 | $72,461 | Direct |
| Jan 6, 2026 | RGNX REGENXBIO Inc. | Award(A) | 73,749 | - | $0 | Direct |
| Sep 1, 2025 | RGNX REGENXBIO Inc. | Tax Payment(F) | 4,901 | $8.93 | $43,766 | Direct |
| Jun 17, 2025 | AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,100 | - | - | Direct |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | Exercise(M) | 3,167 | - | - | Direct |
| Jan 2, 2025 | RGNX REGENXBIO Inc. | Award(A) Stock Options (Right to buy) | 62,547 | - | - | Direct |
| Sep 16, 2024 | RGNX REGENXBIO Inc. | Award(A) | 58,869 | - | $0 | Direct |
1-8 of 8 transactions
About Chan Mitchell
Chan Mitchell (SEC CIK 0001789335) files insider reports with the SEC as Chief Financial Officer of REGENXBIO Inc. (RGNX) and Director of Avalo Therapeutics, Inc. (AVTX).
Signal8 holds 9 ownership filings by Chan Mitchell (1 Form 3, 8 Form 4), filed between Sep 18, 2024 and Sep 3, 2026. Those filings report 8 transactions, from Sep 16, 2024 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Chan Mitchell's filings is in ROCKVILLE, MD.
Recent filings by Chan Mitchell
- Sep 1, 2026: Tax withholding of RGNX shares (Form 4, code F).
- May 6, 2026: Open-market sale of AVTX shares (Form 4, code S).
- Jan 6, 2026: Grant or award of RGNX shares (Form 4, code A).
- Sep 1, 2025: Tax withholding of RGNX shares (Form 4, code F).
- Jun 17, 2025: Grant or award of AVTX derivative securities (Form 4, code A).
Other insiders filing for REGENXBIO Inc. (RGNX)
- Malzahn Craig, Chief Technology Officer
- Ciongoli Gregory Austin, Director
- PAKOLA STEVE, Chief Medical Officer
- Christmas Patrick J., Chief Strategy & Legal Officer
- Simpson Curran, Chief Executive Officer
- Tasse Daniel, Director